| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 09/12/2002 | WO2002070502A1 Dimeric isoflavones |
| 09/12/2002 | WO2002070496A1 Nitric oxide donors based on metallic centres |
| 09/12/2002 | WO2002070490A1 Agonists of beta-adrenoceptors |
| 09/12/2002 | WO2002070485A1 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 09/12/2002 | WO2002070484A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | WO2002070479A1 N-4-piperidinyl compounds as ccr5 modulators |
| 09/12/2002 | WO2002070457A1 Inhibitor of monoamine uptake |
| 09/12/2002 | WO2002070068A2 Lipoxin analogs as novel inhibitors of angiogenesis |
| 09/12/2002 | WO2002070009A1 Preventives/remedies for thickened scar, keloid or chronic arthritic diseases |
| 09/12/2002 | WO2002070008A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | WO2002069998A1 Regulating vegf expression by a protein of the tis11 family |
| 09/12/2002 | WO2002069989A2 Aquatic animal treatment method and composition containing pimenta extract |
| 09/12/2002 | WO2002069980A2 Pharmaceutically effective ginsenosides and their use |
| 09/12/2002 | WO2002069977A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | WO2002069970A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/12/2002 | WO2002069963A2 Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders |
| 09/12/2002 | WO2002069954A1 Composition and methods for the treatment and prevention of bovine mastitis |
| 09/12/2002 | WO2002069926A1 Cosmetic formulations containing flavonoid derivatives |
| 09/12/2002 | WO2002069925A2 Use of $g(a)-lipoic acid in cosmetic or dermatological preparations |
| 09/12/2002 | WO2002069913A1 Skin-improving composition set |
| 09/12/2002 | WO2002069911A2 Active substance combination consisting of $g(a)-liponic acid and bioquinones |
| 09/12/2002 | WO2002069905A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | WO2002069886A2 Modified proteins, designer toxins, and methods of making thereof |
| 09/12/2002 | WO2002069884A2 A sunburn treatment and sunburn prevention method |
| 09/12/2002 | WO2002050030A3 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| 09/12/2002 | WO2002044187A3 Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases |
| 09/12/2002 | WO2002014369A3 Human kininogen d5 domain polypeptides and their use |
| 09/12/2002 | WO2002007748A3 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 09/12/2002 | WO2001089558A3 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
| 09/12/2002 | US20020128527 Use in medicine, pharmacy, biology and technology, friction-reducing additives in engines |
| 09/12/2002 | US20020128471 Useful for treating cellular hyperproliferation |
| 09/12/2002 | US20020128447 Pharmaceutical composition containing IL-10 |
| 09/12/2002 | US20020128444 Controling abberant inflamatory response; obtain animal, incubate with modulator of inflammation, monitor animal for adjustment in inflammatory response |
| 09/12/2002 | US20020128436 Therapeutic composition for use in the treatment of autoimune and rheumatic diseases |
| 09/12/2002 | US20020128306 Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction |
| 09/12/2002 | US20020128298 Methods for increasing leptin levels using nicotinic acid compounds |
| 09/12/2002 | US20020128294 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 09/12/2002 | US20020128287 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
| 09/12/2002 | US20020128279 Potassium channel blocking agents |
| 09/12/2002 | US20020128271 N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| 09/12/2002 | US20020128270 Treating stroke, arhtritis, cancer, tissue ulceration, decubitis ulcer, restenosis, periodontal disease, epidermolysis bullosa, scleritis, psoriasis, AIDS, sepsis, and septic shock. |
| 09/12/2002 | US20020128268 Cosmetic and dermatological preparations; use in nutrition or consumption |
| 09/12/2002 | US20020128262 Styrylbenzodiazepines |
| 09/12/2002 | US20020128240 Treatment of hyperproliferative diseases using active vitamin D analogues |
| 09/12/2002 | US20020128225 Methods and products related to pulmonary delivery of polysaccharides |
| 09/12/2002 | US20020128222 Methods to enhance wound healing and enhanced wound coverage material |
| 09/12/2002 | US20020128217 Therapeutic use of cis-element decoys in vivo |
| 09/12/2002 | US20020127676 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127256 Compositions and methods for treating dermatological disorders |
| 09/12/2002 | US20020127252 Using compounds such as 2,5,7,8-tetramethyl-2-( beta -carboxyethyl)-6-hydroxychroman in cosmetic or dermatological preparations for prophylaxis against dry skin, wrinkle formation and/or pigment disorders |
| 09/12/2002 | US20020127227 Antagonist monoclonal antibodies (mAb) that bind to the RHAMM (receptor for hyaluronic acid mediated motility) receptor; useful for preventing proliferative disease states in a mammal |
| 09/12/2002 | US20020127222 Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas |
| 09/12/2002 | DE10111877A1 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate New imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 09/12/2002 | DE10111728A1 UV-Filter UV-filters |
| 09/12/2002 | DE10111053A1 Wirkstoffkombinationen aus alpha-Liponsäure und Biochinonen Active compound combinations of alpha-lipoic acid and bioquinones |
| 09/12/2002 | DE10111046A1 Cosmetic or dermatological preparations for treating or preventing pigmentation disorders, e.g. freckles or liver spots, containing active agent combination of alpha-lipoic acid and UV-A or UV-B absorber |
| 09/12/2002 | DE10111039A1 Verwendung von Wirkstoffkombinationen aus alpha-Liponsäure und dermatologisch verträglichen Substanzen, die Lichtabsorption im UV-A-Bereich und/oder UV-B-Bereich zeigen, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auwirkungen ultravioletter Strahlung auf die Haut Use of active compound combinations of alpha-lipoic acid and dermatologically acceptable substances which light absorption in the UV-A region and / or UV-B range show, for the preparation of cosmetic or dermatological preparations for the treatment and / or prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging and for the treatment and prophylaxis of the harmful effects of becoming ultraviolet radiation on the skin |
| 09/12/2002 | CA2440803A1 Modulators of chemokine receptor activity |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440161A1 Inhibitor of monoamine uptake |
| 09/12/2002 | CA2440038A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439933A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | CA2439854A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 09/12/2002 | CA2439691A1 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | CA2439687A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | CA2439594A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/11/2002 | EP1238674A2 Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF |
| 09/11/2002 | EP1238655A1 Composition containing a derivative of polyamino acids, and use of this compound to combat skin wrinkles |
| 09/11/2002 | EP1238652A1 Compositions for peeling |
| 09/11/2002 | EP1238647A1 Use of polyaminoacid derivatives as hydrating agents and cosmetic and pharmaceutical compositions containing them |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1238071A2 Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses |
| 09/11/2002 | EP1238016A1 Substituted phthalocyanines and their precursors |
| 09/11/2002 | EP1237917A2 Protein c derivatives |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237889A1 Antibiotic sultam and sultone derived oxazolidinones |
| 09/11/2002 | EP1237880A2 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 09/11/2002 | EP1237877A2 Carboxamide-substituted benzimidazol derivatives, methods for the production thereof and their use as medicaments |
| 09/11/2002 | EP1237876A1 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses |
| 09/11/2002 | EP1237874A2 Selective neurokinin antagonists |
| 09/11/2002 | EP1237869A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 09/11/2002 | EP1237845A1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/11/2002 | EP1237582A2 Methods for introducing genes into mammalian subjects |
| 09/11/2002 | EP1237578A2 Micro-cluster liquids and methods of making and using them |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237565A1 Betaglycan as an inhibin receptor and uses thereof |